ArticleBMJ open2016
Time trends in statin utilisation and coronary mortality in Western European countries.
Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pre-morbid statin use and mortality in trauma: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2026Pooled it
- Association between Lipid Profile and Apolipoproteins with Risk of Diabetic Foot Ulcer: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Trial
- Retinol-binding protein 4 in cardiovascular diseases: mechanisms and therapeutic perspectives.Frontiers in cardiovascular medicine · 2026Review
- Lipid-lowering therapy in Switzerland: time trends in utilization and cost, 2015-2023.Lipids in health and disease · 2025Article
- Innovative methods in evaluating the effects of lipid-lowering medication on bone tissue.Scientific reports · 2025Article
- Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020.Inflammatory bowel diseases · 2025Article
- Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank.European journal of clinical pharmacology · 2024Article
- Article
- Herbal medicine formula Huazhuo Tiaozhi granule ameliorates dyslipidaemia via regulating histone lactylation and miR-155-5p biogenesis.Clinical epigenetics · 2023Article
- Trends and determinants of prevalence, awareness, treatment and control of dyslipidaemia in canton of Geneva, 2005-2019: Potent statins are underused.International journal of cardiology. Cardiovascular risk and prevention · 2023Article
- Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9.Pharmaceutics · 2023Review
- National Trends in Statin Use in Lithuania from 2010 to 2021.Medicina (Kaunas, Lithuania) · 2022Article
- Global Trends in the Epidemiology and Management of Dyslipidemia.Journal of clinical medicine · 2022Review
- Association of blood lipids with coronary artery plaque among Saudi patients referred to computed tomography.BMC cardiovascular disorders · 2022Article
- Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study.Hepatology communications · 2022Article
- Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study.European journal of clinical pharmacology · 2022Article
- Global epidemiology of dyslipidaemias.Nature reviews. Cardiology · 2021Review
- A comparison of carotid atherosclerosis in symptomatic patients between 2002-2005 and 2012-2015 cohorts using multi-contrast magnetic resonance vessel wall imaging.Journal of geriatric cardiology : JGC · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine whether there is a relation between statin utilisation and coronary heart disease (CHD) mortality in populations with different levels of coronary risk, and whether the relation changes over time.
designEcological study using national databases of dispensed medicines and mortality rates.
settingWestern European countries with similar public health systems.
main outcome measuresPopulation CHD mortality rates (rate/100,000) as a proxy for population coronary risk level, and statin utilisation expressed as Defined Daily Dose per one Thousand Inhabitants per Day (DDD/TID), in each country, for each year between 2000 and 2012. Spearman's correlation coefficients between CHD mortality and statin utilisation were calculated. Linear regression analysis was used to assess the relation between changes in CHD mortality and statin utilisation over the years.
results12 countries were included in the study. There was a wide range of CHD mortality reduction between the years 2000 and 2012 (from 25.9% in Italy to 57.9% in Denmark) and statin utilisation increase (from 121% in Belgium to 1263% in Denmark). No statistically significant relations were found between CHD mortality rates and statin utilisation, nor between changes in CHD and changes in statin utilisation in the countries over the years 2000 and 2012.
conclusionsAmong the Western European countries studied, the large increase in statin utilisation between 2000 and 2012 was not associated with CHD mortality, nor with its rate of change over the years. Factors different from the individual coronary risk, such as population ageing, health authority programmes, guidelines, media attention and pharmaceutical industry marketing, may have influenced the large increase in statin utilisation. These need to be re-examined with a greater emphasis on prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.